<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">kurskvest</journal-id><journal-title-group><journal-title xml:lang="ru">Человек и его здоровье</journal-title><trans-title-group xml:lang="en"><trans-title>Humans and their health</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1998-5746</issn><issn pub-type="epub">1998-5754</issn><publisher><publisher-name>Kursk State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="edn" pub-id-type="custom">ULGLQJ</article-id><article-id custom-type="elpub" pub-id-type="custom">kurskvest-1497</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАЦЕВТИЧЕСКИЕ НАУКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACEUTICAL SCIENCES</subject></subj-group></article-categories><title-group><article-title>Валидация методики количественного определения рисперидона и палиперидона методом ВЭЖХ</article-title><trans-title-group xml:lang="en"><trans-title>Validation of the quantitative determination of risperidone and paliperidan by HPLC</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-4722-4007</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Булатов</surname><given-names>Руслан Маратович</given-names></name><name name-style="western" xml:lang="en"><surname>Bulatov</surname><given-names>Ruslan M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант кафедры токсикологической химии, ПГФА, г. Пермь</p></bio><bio xml:lang="en"><p>Post-graduate student of the Department of Toxicological Chemistry, PSPA, Perm, Russian Federation</p></bio><email xlink:type="simple">gustavfarm@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5795-0803</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малкова</surname><given-names>Тамара Леонидовна</given-names></name><name name-style="western" xml:lang="en"><surname>Malkova</surname><given-names>Tamara L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р фарм. наук, профессор, зав. кафедрой токсикологической химии, ПГФА, г. Пермь</p></bio><bio xml:lang="en"><p>Dr. Sci (Pharm.), Professor, Head of the Department of Toxicological Chemistry, PSPA, Perm, Russian Federation</p></bio><email xlink:type="simple">kaftox1@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2656-2381</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сабирзянов</surname><given-names>Денис Робертович</given-names></name><name name-style="western" xml:lang="en"><surname>Sabirzyanov</surname><given-names>Denis R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. фарм. наук, доцент кафедры токсикологической химии, ПГФА, г. Пермь</p></bio><bio xml:lang="en"><p>Cand.Sci (Pharm.), Associate Professor of the Department of Toxicological Chemistry, PSPA, Perm, Russian Federation</p></bio><email xlink:type="simple">denissabyrzyanov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Пермская государственная фармацевтическая академия (ПГФА)<country>Россия</country></aff><aff xml:lang="en">Perm State Pharmaceutical Academy (PSPA)<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>05</day><month>02</month><year>2026</year></pub-date><volume>28</volume><issue>4</issue><fpage>131</fpage><lpage>137</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Булатов Р.М., Малкова Т.Л., Сабирзянов Д.Р., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Булатов Р.М., Малкова Т.Л., Сабирзянов Д.Р.</copyright-holder><copyright-holder xml:lang="en">Bulatov R.M., Malkova T.L., Sabirzyanov D.R.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.kursk-vestnik.ru/jour/article/view/1497">https://www.kursk-vestnik.ru/jour/article/view/1497</self-uri><abstract><p>Цель - проведение валидации разработанной методики методом ВЭЖХ для количественного определения рисперидона и палиперидона для химико-токсикологического анализа и лекарственного мониторинга.</p><sec><title>Материал и методы</title><p>Материал и методы. Объектами исследования являлись стандартные образцы рисперидона и палиперидона, модельные смеси для приготовления модельных и холостых растворов.</p></sec><sec><title>Результаты</title><p>Результаты. В процессе валидации оценена специфичность и разделительная способность методики для определения рисперидона и палиперидона. Проведена оценка метрологических характеристик для следующих параметров валидации - линейность, правильность, прецизионность. Коэффициент корелляциия составил более 0,99, открываемость лежит в заданном диапазоне. Рассчитанные данные параметра сходимость соответствуют заданным критериям. Предел количественного опредеения для обоих веществ составил 1 мкг/мл.</p></sec><sec><title>Заключение</title><p>Заключение. Проведена валидация методики количественного определения рисперидона и палиперидона при совместном присутствии в модельных смесях, а также в индивидуальном виде для целей химико-токсикологического анализа и лекарственного мониторинга по ряду параметров.</p></sec></abstract><trans-abstract xml:lang="en"><p>Objective - validation of the developed method by HPLC for the quantitative determination of risperidone and paliperidone for the purposes of chemical-toxicological studies and drug therapeutic monitoring.</p><sec><title>Material and methods</title><p>Material and methods. The objects of the study were standard samples of risperidone and paliperidone, model mixtures for the preparation of model and blank solutions.</p></sec><sec><title>Results</title><p>Results. During the validation process, the specificity and separation ability of the method for the determination of risperidone and paliperidone were evaluated. The metrological characteristics were evaluated for the following validation parameters: linearity, correctness, and precision. The correlation coefficient was more than 0.99, and the openability is in the specified range. The calculated data meets of parameter convergence correspond to the specified criteria.The limit of quantification for both substances was 1 µg/ml.</p></sec><sec><title>Сonclusion</title><p>Сonclusion. The validation of the method for the quantitative determination of risperidone and paliperidone with their combined presence in model mixtures, as well as individually for the purposes of chemical and toxicological analysis and drug monitoring for a number of parameters was carried out.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>высокоэффективная жидкостная хроматография</kwd><kwd>специфичность</kwd><kwd>линейность</kwd><kwd>правильность</kwd><kwd>прецизионность</kwd><kwd>рисперидон</kwd><kwd>палиперидон</kwd></kwd-group><kwd-group xml:lang="en"><kwd>high performance liquid chromatography</kwd><kwd>specificity</kwd><kwd>linearity</kwd><kwd>correctness</kwd><kwd>precision</kwd><kwd>risperidone</kwd><kwd>paliperidone</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Awouters F.H., Lewi P.J. Forty years of antipsychotic Drug research - from haloperidol to paliperidone - with Dr. Paul Janssen. Arzneimittelforschung 2007;57(10):625-632. DOI: 10.1055/s-0031-1296660.</mixed-citation><mixed-citation xml:lang="en">Awouters F.H., Lewi P.J. Forty years of antipsychotic Drug research - from haloperidol to paliperidone - with Dr. Paul Janssen. Arzneimittelforschung 2007;57(10):625-632. DOI: 10.1055/s-0031-1296660.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bridler R., Umbricht D. Atypical antipsychotics in the treatment of schizophrenia. Swiss Med Wkly. 2003;133(5-6):63-76. DOI: 10.4414/smw.2003.10003.</mixed-citation><mixed-citation xml:lang="en">Bridler R., Umbricht D. Atypical antipsychotics in the treatment of schizophrenia. Swiss Med Wkly. 2003;133(5-6):63-76. DOI: 10.4414/smw.2003.10003.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hamann J., Langer B., Leucht S., Busch R., Kissling W. Medical decision making in antipsychotic drug choice for schizophrenia. American Journal of Psychiatry. 2014;161(7):1301-1304. DOI: 10.1176/appi.ajp.161.7.1301.</mixed-citation><mixed-citation xml:lang="en">Hamann J., Langer B., Leucht S., Busch R., Kissling W. Medical decision making in antipsychotic drug choice for schizophrenia. American Journal of Psychiatry. 2014;161(7):1301-1304. DOI: 10.1176/appi.ajp.161.7.1301.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kahn R.S., Fleischhacker W.W., Boter H. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. The Lancet. 2008;371(9618):1085-1097. DOI: 10.1016/S0140-6736(08)60486-9.</mixed-citation><mixed-citation xml:lang="en">Kahn R.S., Fleischhacker W.W., Boter H. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. The Lancet. 2008;371(9618):1085-1097. DOI: 10.1016/S0140-6736(08)60486-9.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Resenchek R.A., Perkins D.O., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine. 2005;353(12):1209-1223. DOI: 10.1056/NEJMoa051688.</mixed-citation><mixed-citation xml:lang="en">Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Resenchek R.A., Perkins D.O., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine. 2005;353(12):1209-1223. DOI: 10.1056/NEJMoa051688.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ananth J., Parameswaran S., Gunatilake S. et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65:464. DOI: 10.4088/jcp.v65n0403.</mixed-citation><mixed-citation xml:lang="en">Ananth J., Parameswaran S., Gunatilake S. et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65:464. DOI: 10.4088/jcp.v65n0403.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Burns M.J. The pharmacology and toxicology of atypical antipsychotic agents. J Toxicol Clin Toxicol. 2001;39:1-14. DOI: 10.1081/clt-100102873.</mixed-citation><mixed-citation xml:lang="en">Burns M.J. The pharmacology and toxicology of atypical antipsychotic agents. J Toxicol Clin Toxicol. 2001;39:1-14. DOI: 10.1081/clt-100102873.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Castro-Villamor М.А., Duenas-Laita А., Martin-Escudero J.C., Perez-Castrillon J.L. New clinical manifestations of acute risperidone poisoning. J. Toxicol. Clin. Toxicol. 1999;37(7):893-895. DOI: 10.1081/clt-100102531.</mixed-citation><mixed-citation xml:lang="en">Castro-Villamor М.А., Duenas-Laita А., Martin-Escudero J.C., Perez-Castrillon J.L. New clinical manifestations of acute risperidone poisoning. J. Toxicol. Clin. Toxicol. 1999;37(7):893-895. DOI: 10.1081/clt-100102531.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Catalano G., Catalano M., Taylor W. Acute risperidone overdose. Clin. Neuropharmacol. 1997;20(1):82-85. DOI: 10.1097/00002826-199702000-00010.</mixed-citation><mixed-citation xml:lang="en">Catalano G., Catalano M., Taylor W. Acute risperidone overdose. Clin. Neuropharmacol. 1997;20(1):82-85. DOI: 10.1097/00002826-199702000-00010.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ravin D.S., Levenson J.W. Fatal cardiac event following of risperidone therapy. Ann. Pharmacother. 1997;31(7/8):867-870. DOI: 10.1177/106002809703100712.</mixed-citation><mixed-citation xml:lang="en">Ravin D.S., Levenson J.W. Fatal cardiac event following of risperidone therapy. Ann. Pharmacother. 1997;31(7/8):867-870. DOI: 10.1177/106002809703100712.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Булатов Р.М., Тарасова И.В., Малкова Т.Л. К вопросу об отравлениях препаратом рисперидон. Научно-практический журнал «Вестник Пермской государственной фармацевтической академии». 2009;(5):158-159</mixed-citation><mixed-citation xml:lang="en">Bulatov R.M., Tarasova I.V., Malkova T.L. On the issue of poisoning with the drug risperidone. Scientific and practical journal "Bulletin of the Perm State Pharmaceutical Academy".2009;5:158-159 (in Russ)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Булатов Р.М. Атипичные нейролептики рисперидон и палиперидон в фармакологическом и химико-токсикологическом отношении. Пермский медицинский журнал. 2011;28(1):140-145. EDN: NDVJKD.</mixed-citation><mixed-citation xml:lang="en">Bulatov R.M. Atypical neuroleptics risperidone and paliperidone in pharmacological and chemical-toxicological terms. Permskiy meditsinskiy zhurnal. 2011;28(1): 140-145 (in Russ). EDN: NDVJKD.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Owen R. T. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. Drugs Today (Barc). 2007;43(4):249-258.</mixed-citation><mixed-citation xml:lang="en">Owen R. T. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. Drugs Today (Barc). 2007;43(4):249-258.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Deyo Z., Dolder C., Nelson M. Paliperidone for schizophrenia. J. Health-System Pharmacy. 2008;65(5): 403-413. DOI: 10.2146/ajhp070261.</mixed-citation><mixed-citation xml:lang="en">Deyo Z., Dolder C., Nelson M. Paliperidone for schizophrenia. J. Health-System Pharmacy. 2008;65(5): 403-413. DOI: 10.2146/ajhp070261.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Булатов Р.М., Малкова Т.Л., Сабирзянов Д.Р. Разработка методики определения рисперидона и палиперидона для целей химико-токсикологического анализа. Сборник материалов III Международной научно-практической конференции «Разработка лекарственных средств». 2024;114-117.</mixed-citation><mixed-citation xml:lang="en">Bulatov R.M., Malkova T.L., Sabirzyanov D.R. Development of a method for determining risperidone and paliperidone for the purposes of chemical-toxicological analysis. Collection of materials from the III International scientific and practical conference "Development of drugs". 2024;114-117 (in Russ)</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Сабирзянов Д.Р., Булатов Р.М., Малкова Т.Л. Разработка методики изолирования рисперидона из мочи для целей лекарственного мониторинга. Кардиоваскулярная терапия и профилактика. 2025;24(S6):236.EDN: JLMPGZ.</mixed-citation><mixed-citation xml:lang="en">Sabirzyanov D.R., Bulatov R.M., Malkova T.L. Development of a method for isolating risperidone from urine for drug monitoring purposes. Kardiovaskulyarnaya terapiya i profilaktika. 2025;24(S6):236 (in Russ). EDN: JLMPGZ.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Государственная Фармакопея Российской Федерации XV изд. ОФС.1.1.0012, ОФС.1.1.0013, ОФС.1.2.1.2.0001, ОФС 1.2.1.2.0003. Федеральная электронная медицинская библиотека. 2023.URL: http://www.femb.ru.</mixed-citation><mixed-citation xml:lang="en">The State Pharmacopoeia of the Russian Federation XV ed. OFS.1.1.0012, OFS.1.1.0013, OFS.1.2.1.2.0001, OFS 1.2.1.2.0003. Federal'naya elektronnaya meditsinskaya biblioteka. 2023 (in Russ). URL: http://www.femb.ru.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
